Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer.
Eleni GkikaElke FiratSonja AdebahrErika GrafIlinca PoppGianluca RadicioniSimon S LoUrsula NestleNils Henrik NicolayGabriele NiedermannDan G DudaAnca-L GrosuPublished in: NPJ precision oncology (2023)
We performed a prospective study of circulating immune cell changes after stereotactic body radiotherapy (SBRT) in 50 early-stage NSCLC patients. We found no significant increase in CD8 + cytotoxic T lymphocytes at first follow-up (the primary endpoint) but detected a significant increase in expanding Ki-67 + CD8 + and Ki-67 + CD4 + T-cell fractions in patients treated with 10 Gy or less per fraction. SBRT can induce significant expansion in circulating effector T-cells immediately post-treatment.
Keyphrases
- early stage
- radiation therapy
- end stage renal disease
- sentinel lymph node
- small cell lung cancer
- ejection fraction
- newly diagnosed
- neoadjuvant chemotherapy
- chronic kidney disease
- locally advanced
- peritoneal dialysis
- prognostic factors
- regulatory t cells
- brain metastases
- squamous cell carcinoma
- dendritic cells
- radiation induced
- rectal cancer
- lymph node
- combination therapy
- tyrosine kinase